Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

Abstract:
Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Company's Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career.

Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

Cambridge, MA | Posted on January 3rd, 2008

"It is a great pleasure to welcome Boyd Clarke as Chairman of our Board of Directors," said Julie A. Olson, PhD, President and Chief Executive Officer at Mersana. "Boyd brings diverse management experience and commercial expertise in areas important to Mersana at our stage of development. His skills complement those of our existing team very well, and we anticipate his strategic leadership will be of considerable value as we advance our pipeline."

Over the past 11 years Mr. Clarke has held the role of Chairman and Chief Executive Officer at several publicly-held biotechnology companies, most recently Neose Technologies. During his four year tenure at Neose, Mr. Clarke led the company from a platform-based discovery operation to a clinical stage development company with multiple product candidates. As President and CEO of Aviron he oversaw the Biological Licensing Application (BLA) submission for the company's lead product and ultimately secured the sale of the vaccine company to MedImmune. He also served as President and CEO of US Bioscience. Mr. Clarke began his pharmaceutical career at Merck, where he held a series of increasingly responsible positions, including President of Pasteur Merieux MSD and Vice President of Merck Vaccines. He holds a Bachelor of Science degree and a Master of Arts degree from the University of Calgary. Mr. Clarke serves on the Board of Directors of QLT, Inc. and Rib-X, and is a past board member of the Biotechnology Industry Association (BIO).

"Mersana's Fleximer(R) technology has the potential to create safer and more efficacious cancer drugs, and the promise of the technology is now being demonstrated in their ongoing clinical studies," stated Boyd Clarke. "I'm excited by the Company's prospects and am looking forward to participating in their continued growth as Chairman."

####

About Mersana Therapeutics, Inc.
Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert material that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer- camptothecin conjugate, which is currently in Phase 1 clinical trials and several preclinical stage oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.

For more information, please click here

Contacts:
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, MA 02139

Tel: 617.498.0020
Fax: 617.498.0109

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Atomic force imaging used to study nematodes: KFU bionanotechnology lab (head - Dr. Rawil Fakhrullin) has obtained 3-D images of nematodes' cuticles February 23rd, 2017

Particle Works creates range of high performance quantum dots February 23rd, 2017

EmTech Asia breaks new barriers with potential applications of space exploration with NASA and MIT February 22nd, 2017

JPK selects compact tensile stage from Deben for their NanoWizardŽ AFM platform to broaden capabilities for materials characterisation February 22nd, 2017

Nanomedicine

Atomic force imaging used to study nematodes: KFU bionanotechnology lab (head - Dr. Rawil Fakhrullin) has obtained 3-D images of nematodes' cuticles February 23rd, 2017

Nominations Invited for $250,000 Kabiller Prize in Nanoscience: Major international prize recognizes a visionary nanotechnology researcher February 20th, 2017

Good vibrations help reveal molecular details: Rice University scientists combine disciplines to pinpoint small structures in unlabeled molecules February 15th, 2017

In-cell molecular sieve from protein crystal February 14th, 2017

Announcements

Atomic force imaging used to study nematodes: KFU bionanotechnology lab (head - Dr. Rawil Fakhrullin) has obtained 3-D images of nematodes' cuticles February 23rd, 2017

Particle Works creates range of high performance quantum dots February 23rd, 2017

GLOBALFOUNDRIES Announces Availability of 45nm RF SOI to Advance 5G Mobile Communications: Optimized RF features deliver high-performance solutions for mmWave beam forming applications in 5G smartphones and base stations February 22nd, 2017

EmTech Asia breaks new barriers with potential applications of space exploration with NASA and MIT February 22nd, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project